Puckettstentoft7561

s proven to be safe for elderly participants with osteoarthritis of the knee, whether it provided extra benefits to exercises alone was unclear. Further research is required to determine the effectiveness of dorsiflexion and optimal range of mobilization.

To compare the clinical outcomes and cement leakage rate between high-viscosity and low-viscosity cement percutaneous vertebroplasty (PVP) with manipulative reduction in the treatment of Kümmell's disease (KD).

PVP using high-viscosity cement (Group H) or low-viscosity cement (Group L) with manipulative reduction was compared in 86 KD patients. Visual Analogue Scale (VAS), Oswestry Disability Index (ODI), vertebral height, kyphosis angle and complications were evaluated and compared preoperative, one day postoperative, and at final follow-up.

The VAS score, ODI score, mean anterior and middle vertebral height variation significantly improved in both groups postoperatively. However, there was no significant difference between the two groups considering the above results preoperative and postoperative. Significantly less cement leakage (13.6%) and shorter operative time (35.6 ± 5.1 min) were observed in Group H when compared with Group L (45.2% and 41.1 ± 5.3 min) (p< 0.05).

The clinical outcomes and radiologic findings of PVP with manipulative reduction was not influenced by cement viscosity. However, high cement viscosity PVP was found to be significant less cement leakage and shorter operative time.

The clinical outcomes and radiologic findings of PVP with manipulative reduction was not influenced by cement viscosity. However, high cement viscosity PVP was found to be significant less cement leakage and shorter operative time.

Approximately 70-80% of breast cancer express ER-alpha and hormonal therapies, given significant improvements in patient survival. SCH66336 supplier About 50% of ER-positive breast cancer patients with advanced disease insensitive to tamoxifen treatment when diagnosed. Recent studies have shown that ERα-36 is a crucial factor in the resistance of tamoxifen.

This study aims to determine the association between ERα-36 expression and denovo resistance of tamoxifen in patients with ER-positive breast cancer.

This study was an observational study using a cross-sectional method and was conducted at Wahidin Sudirohusodo Hospital and Unhas Hospital. ERα-36 protein expression was assessed using an immunohistochemistry assay. The association of ERα-36 expression and resistance of tamoxifen was tested with the Chi-square test.

A total of 50 locally advanced breast cancer cases were included in this study, 22 cases (44%) had overexpression of ERα-36, and 28 cases (56%) had not, 24 cases (48%) had experience resistance to tamoxifen and 26 cases (52%) had not. There was a significant association between ERα-36 expressions and resistance of tamoxifen (p =0.000).

There was an association between the expression of ER-α36 with denovo resistance of tamoxifen in ER-positive breast cancer. ER-α36 could act as a worth considering biomarker for denovo resistance of tamoxifen in therapeutic strategies.

There was an association between the expression of ER-α36 with de novo resistance of tamoxifen in ER-positive breast cancer. ER-α36 could act as a worth considering biomarker for de novo resistance of tamoxifen in therapeutic strategies.

Breast cancer is the most prevalent carcinoma found in Indonesian women, and its incidence remains high worldwide. Lipocalin 2 has been linked with the progression of breast cancer. Matrix metalloproteinase 9 (MMP9) is an enzyme that has an important role in angiogenesis. We investigated the relationship between lipocalin 2 and MMP9 and the ability of lipocalin 2 for predicting MMP9 levels in female patients with breast cancer.

A total of 55 female patients with breast cancer were enrolled in this cross-sectional study. Lipocalin 2 and MMP9 were measured by enzyme-linked immunosorbent assay.

Lipocalin 2 was significantly correlated with MMP9 levels (r =0.756, p <0.001). Lipocalin 2 levels could describe the MMP9 levels (

Cancer is a disease caused by abnormal growth of body cells that turn malignant and continue to grow uncontrollably. One of the treatments for breast cancer is mastectomy. The quickness of decision-making determines the survival rate of prognosis patients.

This study aimed to determine the relationship of self-acceptance with decision-making duration in cancer patients to perform a mastectomy.

An analytic observation method with cross-sectional design. The samples were taken by purposive sampling method with 50 samples of breast cancer patients. Data collected include age, last level of education, marital status, profession, stage of cancer during mastectomy, self-acceptance score, and decision-making duration to perform a mastectomy.

The data analyzed with the Kruskal-Wallis test. The test showed the relationship of self-acceptance (p =0.027) with decision-making duration in breast cancer patients to perform a mastectomy.

In conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

In conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

The overproduction of interleukin-6 (IL-6) in breast cancer cases can aggravate metastases. In comparison, the production of T lymphocytes plays a role in suppressing the development of tumor cells. Honey as a complementary therapy is expected to reduce the overproduction of IL-6 and facilitate the production of T lymphocytes in breast cancer cases.

This study aims to determine the effect of Dorsata honey (DH) as a complementary therapy to IL-6 levels and T lymphocytes of post-chemotherapy in breast cancer.

This study was a quasi-experimental approach that employed a pretest-posttest group control design. As many as 30 post-chemotherapy breast cancer patients at the Central Hospital in Eastern Indonesia were randomly selected into a control group of 15 participants. Additionally, an intervention group of 15 participants was given DH orally three times a day at a dose of 15ml. The blood sample was taken two times, day 0 of the chemotherapy and day 16 (post-chemotherapy). The level of IL-6 was measured by ELISA, while the data were analyzed by Wilcoxon, independent T-test, and Mann-Whitney test.